NewcelX Ltd.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Ronen Twito
- Full Time Employees
- 11
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- The Circle 6 Zurich Switzerland 8058
- IPO Date
- Oct 24, 2025
- CIK
- 0001783036
- Website
- newcelx.com
- Similar Companies
- Business
- NewcelX Ltd (Nasdaq: NCEL), formerly Kadimastem Ltd (TASE: KDST), is a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies derived from human embryonic stem cells (hESCs) for neurodegenerative diseases and metabolic disorders, including amyotrophic lateral sclerosis (ALS) and Type 1 diabetes. The company's core pipeline includes AstroRx, clinical-grade human astrocytes designed to support motor neuron survival in ALS patients through intrathecal transplantation; IsletRx, insulin-secreting pancreatic islet-like cells for blood glucose regulation in diabetes without lifelong immunosuppression; and exploratory programs leveraging its proprietary cell differentiation platform for additional glial and endocrine cell products. These scalable, industrialized therapies are produced under GMP conditions for broad commercial applicability as stable off-the-shelf treatments. In October 2025, Kadimastem completed a definitive merger with NLS Pharmaceutics Ltd, forming NewcelX Ltd and commencing Nasdaq trading under the NCEL ticker following shareholder approvals, Nasdaq listing clearance, a 1-for-10 reverse stock split, and a share exchange ratio of 0.706 NewcelX shares per Kadimastem ordinary share. This strategic combination integrates Kadimastem's cell therapy assets with NLS's neuroscience expertise, enabling U.S. capital market access, Phase 2a trial initiation for AstroRx in ALS, and pre-IND advancement for IsletRx with the FDA targeted for early 2025. Recent developments also encompass a manufacturing partnership with Pluri CDMO for AstroRx and IsletRx production, BIRD Foundation support for the ITOL-102 diabetes program, and a collaboration with TargetGene for next-generation gene-edited cell therapies. Founded in 2008 and originally headquartered in Ness Ziona, Israel, at Pinhas Sapir Street in the Weizmann Science Park, NewcelX maintains research and development operations there alongside its corporate headquarters in Zurich, Switzerland. The company targets global markets in regenerative medicine, serving patients with incurable neurodegenerative and insulin-dependent conditions through its platform technology that differentiates pluripotent stem cells into functional, transplantable cell types. Leadership includes Executive Chairman and CEO Ronen Twito, Chief Scientific Officer Prof. Michel Revel, and a board featuring experts in biotechnology and clinical development.
NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes
NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026
NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference
NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference
NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing
NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes
NLS Pharmaceutics Ltd. (NASDAQ:NCEL) Short Interest Update
NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy
NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences
NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression
Contrasting NLS Pharmaceutics (NASDAQ:NCEL) and 4D Molecular Therapeutics (NASDAQ:FDMT)
NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board
Analyzing NLS Pharmaceutics (NASDAQ:NCEL) & USANA Health Sciences (NYSE:USNA)
NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China
Comparing NLS Pharmaceutics (NASDAQ:NCEL) & Akebia Therapeutics (NASDAQ:AKBA)
NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute
NewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory Board
NewcelX CEO Issues Letter to Shareholders
NewcelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd. and Kadimastem Ltd.